Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
1. A method of treating fibrosis, comprising administering an effective amount of a biologically active modified relaxin polypeptide comprising a non-naturally encoded amino acid, wherein:
(a) the modified relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue 1 and having zero, one or two additional amino acid changes in said relaxin A chain and having zero, one or two additional amino acid changes in said relaxin B chain, wherein each of said amino acid changes is independently a substitution, insertion or deletion;
(b) said non-naturally encoded amino acid has the structure:
wherein the R group is any substituent other than the side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine; and
(c) said non-naturally encoded amino acid is linked to a pharmacokinetic enhancer comprising a peptide component between 4 and 8 amino acids and a half-life extending moiety, comprising a fatty acid of Formula I:
-Cn-COOH (Formula I)
wherein n is between 12 and 16,
said peptide component comprises Glu γ , and
wherein said modified relaxin polypeptide is administered to a patient suffering from fibrosis.
2. The method of claim 1 , wherein said non-naturally encoded amino acid comprises a phenylalanine derivative.
3. The method of claim 1 , wherein said relaxin A chain polypeptide comprises SEQ ID NO: 35, and said relaxin B chain polypeptide comprises SEQ ID NO: 5 or SEQ ID NO: 6.
4. The method of claim 1 , wherein said peptide component comprises GGGGS-Gluγ (SEQ ID NO: 139), DRDDRD (SEQ ID NO: 102), KKKKKK-Gluγ (SEQ ID NO: 103), GGGEEE-Gluγ (SEQ ID NO: 105), EEEGGG-Gluγ (SEQ ID NO: 106), KKKGGG-Gluγ (SEQ ID NO: 107), GGGKKK-Gluγ (SEQ ID NO: 109), Sar-Sar-Sar-Sar-Ser-Gluγ (SEQ ID NO: 112), Sar-Sar-Sar-Glu-Glu-Gluγ (SEQ ID NO: 113), KSGGSGG-Gluγ (SEQ ID NO: 117), dKdKdKdKdKdK-Gluγ (SEQ ID NO: 120), EEEGGG-d Gluγ (SEQ ID NO: 128), EGGGGSK-Gluγ (SEQ ID NO: 130), EEEEEE-Gluγ (SEQ ID NO: 131), KK-Gluγ (SEQ ID NO: 140), KGPKGP-Gluγ (SEQ ID NO: 146), SGGGS-Gluγ (SEQ ID NO: 147), KGGGS-Gluγ (SEQ ID NO: 148), KGGGSE-Gluγ (SEQ ID NO: 149), GSPGSP-Gluγ (SEQ ID NO: 150), GGGGP-Gluγ (SEQ ID NO: 151), EGGS-Gluγ (SEQ ID NO: 152), EGGGP-Gluγ (SEQ ID NO: 153), KGPGSE-Gluγ (SEQ ID NO: 154), Spermine-Gluγ, or KKGGS-Gluγ (SEQ ID NO: 156).
5. The method of claim 1 , wherein the modified relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue 1, wherein said non-naturally encoded amino acid is linked to said pharmacokinetic enhancer and said pharmacokinetic enhancer comprises the peptide component GGGGS-Gluγ (SEQ ID NO: 139).
6. The method of claim 1 , wherein said pharmacokinetic enhancer comprises:
wherein the aminooxy group is linked to the non-natural amino acid in said modified relaxin polypeptide.
7. The method of claim 1 , wherein the modified relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue 1;
said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine and is linked to said pharmacokinetic enhancer which comprises
a peptide component comprising GGGGS-Gluγ (SEQ ID NO: 139); and
a half-life extending moiety comprising —C14-COOH.
8. The method of claim 1 , wherein the modified relaxin comprises a relaxin A chain polypeptide of SEQ ID NO: 35, and a relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, wherein a para-acetyl-L-phenylalanine is located at position 1 of the relaxin A chain polypeptide, which para-acetyl-L-phenylalanine is linked to the pharmacokinetic enhancer GGGGS-Gluγ (SEQ ID NO: 139)-C14-COOH, as depicted in Formula III:
9. A method of treating a cardiovascular disease comprising administering an effective amount of a biologically active modified relaxin polypeptide comprising a non-naturally encoded amino acid, wherein:
(a) the modified relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue 1, and having zero, one or two additional amino acid changes in said relaxin A chain and having zero, one or two additional amino acid changes in said relaxin B chain, wherein each of said amino acid changes is independently a substitution, insertion or deletion;
(b) said non-naturally encoded amino acid has the structure:
wherein the R group is any substituent other than the side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine; and
(c) said non-naturally encoded amino acid is linked to a pharmacokinetic enhancer comprising a peptide component between 4 and 8 amino acids and a half-life extending moiety, comprising a fatty acid of Formula I:
-Cn-COOH (Formula I)
wherein n is between 12 and 16,
said peptide component comprises Glu γ , and
further wherein said modified relaxin polypeptide is administered to a patient suffering from a cardiovascular disease.
10. The method of claim 9 , wherein said cardiovascular disease is selected from coronary artery disease, heart attack, arrhythmia, heart failure, cardio-renal syndrome, post myocardial remodeling, and cardiomyopathy.
11. The method of claim 9 , wherein said non-naturally encoded amino acid comprises a phenylalanine derivative.
12. The method of claim 9 , wherein said relaxin A chain polypeptide comprises SEQ ID NO: 35, and said relaxin B chain polypeptide comprises SEQ ID NO: 5 or SEQ ID NO: 6.
13. The method of claim 9 , wherein said peptide component comprises GGGGS-Gluγ (SEQ ID NO: 139), DRDDRD (SEQ ID NO: 102), KKKKKK-Gluγ (SEQ ID NO: 103), GGGEEE-Gluγ (SEQ ID NO: 105), EEEGGG-Gluγ (SEQ ID NO: 106), KKKGGG-Gluγ (SEQ ID NO: 107), GGGKKK-Gluγ (SEQ ID NO: 109), Sar-Sar-Sar-Sar-Ser-Gluγ (SEQ ID NO: 112), Sar-Sar-Sar-Glu-Glu-Gluγ (SEQ ID NO: 113), KSGGSGG-Gluγ (SEQ ID NO: 117), dKdKdKdKdKdK-Gluγ (SEQ ID NO: 120), EEEGGG-d Gluγ (SEQ ID NO: 128), EGGGGSK-Gluγ (SEQ ID NO: 130), EEEEEE-Gluγ (SEQ ID NO: 131), KK-Gluγ (SEQ ID NO: 140), KGPKGP-Gluγ (SEQ ID NO: 146), SGGGS-Gluγ (SEQ ID NO: 147), KGGGS-Gluγ (SEQ ID NO: 148), KGGGSE-Gluγ (SEQ ID NO: 149), GSPGSP-Gluγ (SEQ ID NO: 150), GGGGP-Gluγ (SEQ ID NO: 151), EGGS-Gluγ (SEQ ID NO: 152), EGGGP-Gluγ (SEQ ID NO: 153), KGPGSE-Gluγ (SEQ ID NO: 154), Spermine-Gluγ, or KKGGS-Gluγ (SEQ ID NO: 156).
14. The method of claim 9 , wherein the modified relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue 1, wherein said non-naturally encoded amino acid is linked to said pharmacokinetic enhancer and said pharmacokinetic enhancer comprises the peptide component GGGGS-Gluγ (SEQ ID NO: 139).
15. The method of claim 9 , wherein said pharmacokinetic enhancer comprises:
wherein the aminooxy group is linked to the non-natural amino acid in said modified relaxin polypeptide.
16. The method of claim 9 , wherein the modified relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue 1;
said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine and is linked to said pharmacokinetic enhancer which comprises
a peptide component comprising GGGGS-Gluγ (SEQ ID NO: 139); and
a half-life extending moiety comprising —C14-COOH.
17. The method of claim 9 , wherein the modified relaxin comprises a relaxin A chain polypeptide of SEQ ID NO: 35, and a relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, wherein a para-acetyl-L-phenylalanine is located at position 1 of the relaxin A chain polypeptide, which para-acetyl-L-phenylalanine is linked to the pharmacokinetic enhancer GGGGS-Gluγ (SEQ ID NO: 139)-C14-COOH, as depicted in Formula III:
18. A method of treating heart failure comprising administering an effective amount of a biologically active modified relaxin polypeptide comprising a non-naturally encoded amino acid, wherein:
(a) the modified relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue land having zero, one or two additional amino acid changes in said relaxin A chain and having zero, one or two additional amino acid changes in said relaxin B chain, wherein each of said amino acid changes is independently a substitution, insertion or deletion;
(b) said non-naturally encoded amino acid has the structure:
wherein the R group is any substituent other than the side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine; and
(c) said non-naturally encoded amino acid is linked to a pharmacokinetic enhancer comprising a peptide component between 4 and 8 amino acids and a half-life extending moiety, comprising a fatty acid of Formula I:
-Cn-COOH (Formula I)
wherein n is between 12 and 16,
said peptide component comprises Glu γ , and
further wherein said modified relaxin polypeptide is administered to a patient suffering from heart failure.
19. The method of claim 18 , wherein said heart failure is selected from advanced heart failure, heart failure with impaired kidney function, chronic heart failure, chronic heart failure with mid-range ejection fraction (HFmEF), acute heart failure, post-acute heart failure, compensated heart failure, decompensated heart failure, right heart failure, left heart failure, global heart failure, heart failure associated with congenital heart defects, heart failure associated with heart valve defects, heart failure associated with combined heart valve defects, diabetic heart failure, heart failure associated with cardiac storage disorders, diastolic heart failure, systolic heart failure, heart failure with preserved ejection fraction (HFpEF), and heart failure with reduced ejection fraction (HFrEF).
20. The method of claim 18 , wherein said non-naturally encoded amino acid comprises a phenylalanine derivative.
21. The method of claim 18 , wherein said relaxin A chain polypeptide comprises SEQ ID NO: 35, and said relaxin B chain polypeptide comprises SEQ ID NO: 5 or SEQ ID NO: 6.
22. The method of claim 18 , wherein said peptide component comprises GGGGS-Gluγ (SEQ ID NO: 139), DRDDRD (SEQ ID NO: 102), KKKKKK-Gluγ (SEQ ID NO: 103), GGGEEE-Gluγ (SEQ ID NO: 105), EEEGGG-Gluγ (SEQ ID NO: 106), KKKGGG-Gluγ (SEQ ID NO: 107), GGGKKK-Gluγ (SEQ ID NO: 109), Sar-Sar-Sar-Sar-Ser-Gluγ (SEQ ID NO: 112), Sar-Sar-Sar-Glu-Glu-Gluγ (SEQ ID NO: 113), KSGGSGG-Gluγ (SEQ ID NO: 117), dKdKdKdKdKdK-Gluγ (SEQ ID NO: 120), EEEGGG-d Gluγ (SEQ ID NO: 128), EGGGGSK-Gluγ (SEQ ID NO: 130), EEEEEE-Gluγ (SEQ ID NO: 131), KK-Gluγ (SEQ ID NO: 140), KGPKGP-Gluγ (SEQ ID NO: 146), SGGGS-Gluγ (SEQ ID NO: 147), KGGGS-Gluγ (SEQ ID NO: 148), KGGGSE-Gluγ (SEQ ID NO: 149), GSPGSP-Gluγ (SEQ ID NO: 150), GGGGP-Gluγ (SEQ ID NO: 151), EGGS-Gluγ (SEQ ID NO: 152), EGGGP-Gluγ (SEQ ID NO: 153), KGPGSE-Gluγ (SEQ ID NO: 154), Spermine-Gluγ, or KKGGS-Gluγ (SEQ ID NO: 156).
23. The method of claim 18 , wherein the modified relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue 1, wherein said non-naturally encoded amino acid is linked to said pharmacokinetic enhancer and said pharmacokinetic enhancer comprises the peptide component GGGGS-Gluγ (SEQ ID NO: 139).
24. The method of claim 18 , wherein said pharmacokinetic enhancer comprises:
wherein the aminooxy group is linked to the non-natural amino acid in said modified relaxin polypeptide.
25. The method of claim 18 , wherein the modified polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue 1;
said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine and is linked to said pharmacokinetic enhancer which comprises
a peptide component comprising GGGGS-Gluγ (SEQ ID NO: 139); and
a half-life extending moiety comprising —C14-COOH.
26. The method of claim 18 , wherein the modified relaxin comprises a relaxin A chain polypeptide of SEQ ID NO: 35, and a relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, wherein a para-acetyl-L-phenylalanine is located at position 1 of the relaxin A chain polypeptide, which para-acetyl-L-phenylalanine is linked to the pharmacokinetic enhancer GGGGS-Gluγ (SEQ ID NO: 139)-C14-COOH, as depicted in Formula III: